- Home
- YYAI vs TNXP Comparison
YYAI vs TNXP Comparison
Compare YYAI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- TNXP
- Stock Information
- Founded
- YYAI 2015
- TNXP 2007
- Country
- YYAI United States
- TNXP United States
- Employees
- YYAI N/A
- TNXP N/A
- Industry
- YYAI
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- TNXP Health Care
- Exchange
- YYAI NYSE
- TNXP Nasdaq
- Market Cap
- YYAI 19.5M
- TNXP 19.5M
- IPO Year
- YYAI N/A
- TNXP N/A
- Fundamental
- Price
- YYAI $5.03
- TNXP $0.13
- Analyst Decision
- YYAI
- TNXP Strong Buy
- Analyst Count
- YYAI 0
- TNXP 2
- Target Price
- YYAI N/A
- TNXP $53.50
- AVG Volume (30 Days)
- YYAI 248.1K
- TNXP 13.8M
- Earning Date
- YYAI 11-26-2024
- TNXP 11-12-2024
- Dividend Yield
- YYAI N/A
- TNXP N/A
- EPS Growth
- YYAI N/A
- TNXP N/A
- EPS
- YYAI N/A
- TNXP N/A
- Revenue
- YYAI $5,982,717.00
- TNXP $11,291,000.00
- Revenue This Year
- YYAI N/A
- TNXP $62.53
- Revenue Next Year
- YYAI N/A
- TNXP $26.17
- P/E Ratio
- YYAI N/A
- TNXP N/A
- Revenue Growth
- YYAI N/A
- TNXP 183.05
- 52 Week Low
- YYAI $2.90
- TNXP $0.12
- 52 Week High
- YYAI $53.00
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- YYAI 46.94
- TNXP 33.87
- Support Level
- YYAI $4.03
- TNXP $0.13
- Resistance Level
- YYAI $5.20
- TNXP $0.15
- Average True Range (ATR)
- YYAI 0.94
- TNXP 0.01
- MACD
- YYAI 0.13
- TNXP 0.00
- Stochastic Oscillator
- YYAI 60.96
- TNXP 4.86
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.